The E119D neuraminidase mutation identified in a multidrug-resistant influenza A(H1N1)pdm09 isolate severely alters viral fitness in vitro and in animal models

Antiviral Research

Volumn 132, Issue , 2016, Pages 6-12

  Abed, Yacine ^a   Bouhy, Xavier ^a   L'Huillier, Arnaud G ^b   Rhéaume, Chantal ^a   Pizzorno, Andrés ^a   Retamal, Miguel ^a   Fage, Clément ^a   Dubé, Karen ^c   Joly, Marie Hélène ^c   Beaulieu, Edith ^c   Mallett, Corey ^c   Kaiser, Laurent ^b   Boivin, Guy ^a  

^a LAVAL UNIVERSITY   (Canada)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c GLAXOSMITHKLINE   (Canada)

Author keywords

A(H1N1)pdm09; E119D; Influenza; Neuraminidase; Resistance; Zanamivir

Indexed keywords

E119D NEURAMINIDASE; LANINAMIVIR; OSELTAMIVIR; PERAMIVIR; RECOMBINANT PROTEIN; SIALIDASE; UNCLASSIFIED DRUG; ZANAMIVIR; ANTIVIRUS AGENT; NA PROTEIN, INFLUENZA A VIRUS; VIRAL PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CROSS RESISTANCE; FEMALE; HARTLEY GUINEA PIG; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H1N1)PDM09; MDCK CELL LINE; MORTALITY; MOUSE; MULTIDRUG RESISTANCE; MUTATIONAL ANALYSIS; NONHUMAN; NOSE SMEAR; PRIORITY JOURNAL; SEROCONVERSION; VIRUS ISOLATION; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS TITRATION; VIRUS TRANSMISSION; VIRUS VIRULENCE; WILD TYPE; AMINO ACID SUBSTITUTION; ANIMAL; ANTIVIRAL RESISTANCE; CELL LINE; CODON; DRUG EFFECTS; GENETIC RECOMBINATION; GENETICS; GUINEA PIG; MUTATION; ORTHOMYXOVIRUS INFECTION; PHYSIOLOGY; REPRODUCTIVE FITNESS; VIROLOGY; VIRUS LOAD;

AMINO ACID SUBSTITUTION; ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CODON; DRUG RESISTANCE, VIRAL; GENETIC FITNESS; GUINEA PIGS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; MICE; MUTATION; NEURAMINIDASE; ORTHOMYXOVIRIDAE INFECTIONS; RECOMBINATION, GENETIC; VIRAL LOAD; VIRAL PROTEINS;

EID: 84969706266     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2016.05.006     Document Type: Article

References (28)

1. Y. Abed, A. Pizzorno, X. Bouhy, C. Rheaume, and G. Boivin Impact of potential permissive neuraminidase mutations on viral fitness of the H275Y oseltamivir-resistant influenza A(H1N1)pdm09 virus in vitro, in mice and in ferrets J. Virol. 88 2014 1652 1658
2. Y.H. Baek, M.S. Song, E.Y. Lee, Y.I. Kim, E.H. Kim, S.J. Park, K.J. Park, H.I. Kwon, P.N. Pascua, G.J. Lim, S. Kim, S.W. Yoon, M.H. Kim, R.J. Webby, and Y.K. Choi Profiling and characterization of influenza virus N1 strains potentially resistant to multiple neuraminidase inhibitors J. Virol. 89 2015 287 299
3. D. Birnkrant, and E. Cox The emergency use authorization of peramivir for treatment of 2009 H1N1 influenza N. Engl. J. Med. 361 2009 2204 2207
4. J.D. Bloom, J.S. Nayak, and D. Baltimore A computational-experimental approach identifies mutations that enhance surface expression of an oseltamivir-resistant influenza neuraminidase PloS One 6 2011 e22201
5. C. Chambers, D.M. Skowronski, S. Sabaiduc, A.L. Winter, J.A. Dickinson, G. De Serres, J.B. Gubbay, S.J. Drews, C. Martineau, A. Eshaghi, M. Krajden, N. Bastien, and Y. Li Interim estimates of 2015/16 vaccine effectiveness against influenza A(H1N1)pdm09, Canada Euro Surveill. 21 11 February 2016 pii 30168
6. S.M. Choi, A.A. Boudreault, H. Xie, J.A. Englund, L. Corey, and M. Boeckh Differences in clinical outcomes after 2009 influenza A/H1N1 and seasonal influenza among hematopoietic cell transplant recipients Blood 117 2011 5050 5056
7. M.C. Christman, A. Kedwaii, J. Xu, R.O. Donis, and G. Lu Pandemic (H1N1) 2009 virus revisited: an evolutionary retrospective Infect. Genet. Evol. J Mol. Epidemiol. Evol. Gen. Infect. Dis. 11 2011 803 811
8. P.M. Colman, P.A. Hoyne, and M.C. Lawrence Sequence and structure alignment of paramyxovirus hemagglutinin-neuraminidase with influenza virus neuraminidase J. Virol. 67 1993 2972 2980
9. G. Dong, C. Peng, J. Luo, C. Wang, L. Han, B. Wu, G. Ji, and H. He Adamantane-resistant influenza a viruses in the world (1902-2013): frequency and distribution of M2 gene mutations PLoS One 10 2015 e0119115
10. J. Dunning, J.K. Baillie, B. Cao, and F.G. Hayden Antiviral combinations for severe influenza Lancet Infect. Dis. 14 2014 1259 1270
11. S. Epperson, L. Blanton, K. Kniss, D. Mustaquim, C. Steffens, T. Wallis, R. Dhara, M. Leon, A. Perez, S.S. Chaves, A.A. Elal, L. Gubareva, X. Xu, J. Villanueva, J. Bresee, N. Cox, L. Finelli, and L. Brammer Influenza activity - United States, 2013-14 season and composition of the 2014-15 influenza vaccines MMWR Morb. Mortal. Wkly. Rep. 63 2014 483 490
12. M.E. Hamelin, M. Baz, Y. Abed, C. Couture, P. Joubert, E. Beaulieu, N. Bellerose, M. Plante, C. Mallett, G. Schumer, G.P. Kobinger, and G. Boivin Oseltamivir-resistant pandemic A/H1N1 virus is as virulent as its wild-type counterpart in mice and ferrets PLoS Pathog. 6 2010 e1001015
13. S. Hatakeyama, Y. Sakai-Tagawa, M. Kiso, H. Goto, C. Kawakami, K. Mitamura, N. Sugaya, Y. Suzuki, and Y. Kawaoka Enhanced expression of an alpha2,6-linked sialic acid on MDCK cells improves isolation of human influenza viruses and evaluation of their sensitivity to a neuraminidase inhibitor J. Clin. Microbiol. 43 2005 4139 4146
14. F.G. Hayden, and P. Palese Influenza virus R.W.J. Douglas, D. Richman, F.G. Hayden, Clinical Virology second ed. 2002 ASM Press Washington D.C. 891 920
15. S. Kubo, T. Tomozawa, M. Kakuta, A. Tokumitsu, and M. Yamashita Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration Antimicrob. Agents Chemother. 54 2010 1256 1264
16. A.G. L'Huillier, Y. Abed, T.J. Petty, S. Cordey, Y. Thomas, X. Bouhy, M. Schibler, A. Simon, Y. Chalandon, C. van Delden, E. Zdobnov, P. Boquete-Suter, G. Boivin, and L. Kaiser The E119D Neuraminidase mutation confers pan-resistance to neuraminidase inhibitors in an A(H1N1)pdm09 isolate from a stem-cell transplant recipient J. Infect. Dis. 212 2015 1726 1732
17. M.J. Memoli, A.S. Davis, K. Proudfoot, D.S. Chertow, R.J. Hrabal, T. Bristol, and J.K. Taubenberger Multidrug-resistant 2009 pandemic influenza A(H1N1) viruses maintain fitness and transmissibility in ferrets J. Infect. Dis. 203 2011 348 357
18. A. Moscona Neuraminidase inhibitors for influenza N. Engl. J. Med. 353 2005 1363 1373
19. A. Otte, and G. Gabriel 2009 pandemic H1N1 influenza A virus strains display differential pathogenicity in C57BL/6J but not BALB/c mice Virulence 2 2011 563 566
20. A. Pizzorno, X. Bouhy, Y. Abed, and G. Boivin Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors J. Infect. Dis. 203 2011 25 31
21. A. Pizzorno, Y. Abed, C. Rheaume, X. Bouhy, and G. Boivin Evaluation of recombinant 2009 pandemic influenza A (H1N1) viruses harboring zanamivir resistance mutations in mice and ferrets Antimicrob. Agents Chemother. 57 2013 1784 1789
22. Press release FDA approves Rapivab to treat flu infection Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427755.htm 2014
23. M. Samson, Y. Abed, F.M. Desrochers, S. Hamilton, A. Luttick, S.P. Tucker, M.J. Pryor, and G. Boivin Characterization of drug-resistant influenza virus A(H1N1) and A(H3N2) variants selected in vitro with laninamivir Antimicrob. Agents Chemother. 58 2014 5220 5228
24. C.W. Seibert, M. Kaminski, J. Philipp, D. Rubbenstroth, R.A. Albrecht, F. Schwalm, S. Stertz, R.A. Medina, G. Kochs, A. Garcia-Sastre, P. Staeheli, and P. Palese Oseltamivir-resistant variants of the 2009 pandemic H1N1 influenza A virus are not attenuated in the guinea pig and ferret transmission models J. Virol. 84 2010 11219 11226
25. D. Tamura, R.L. DeBiasi, M. Okomo-Adhiambo, V.P. Mishin, A.P. Campbell, B. Loechelt, B.L. Wiedermann, A.M. Fry, and L.V. Gubareva Emergence of multidrug-resistant influenza A(H1N1)pdm09 virus variants in an immunocompromised child treated with oseltamivir and zanamivir J. Infect. Dis. 212 2015 1209 1213
26. A. Watanabe, S.C. Chang, M.J. Kim, D.W. Chu, and Y. Ohashi Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: a double-blind, randomized, noninferiority clinical trial Clin. Infect. Dis. 51 2010 1167 1175
27. D.D. Wong, K.T. Choy, R.W. Chan, S.F. Sia, H.P. Chiu, P.P. Cheung, M.C. Chan, J.S. Peiris, and H.L. Yen Comparable fitness and transmissibility between oseltamivir-resistant pandemic 2009 and seasonal H1N1 influenza viruses with the H275Y neuraminidase mutation J. Virol. 86 2012 10558 10570
28. Z. Yang, G. Yang, and L. Zhou Mutation effects of neuraminidases and their docking with ligands: a molecular dynamics and free energy calculation study J. Comp. Aided Mol. Des. 27 2013 935 950